Our attorneys are leaders in using inter partes review (IPR) to address the validity of issued patents. Our team has the strategic foresight and the extensive knowledge of patent law required to handle post-issuance proceedings before the Patent Trial and Appeal Board (PTAB).
Husch Blackwell initiated the first pharmaceutical-related inter partes review under the America Invents Act of 2011, securing a decision that invalidated all 58 of the challenged claims on behalf of our client. Since then, we have secured many additional positive outcomes, thanks to litigation plans that carefully consider timing and estoppel, the ability to stay concurrent litigation, and consistency with concurrent litigation involving the subject patents.